CO-STAR: Surgical conversion feasibility trial of sintilimab (PD-1 inhibitor) combined with Nab-PTX, S-1 and apatinib for the first-line treatment of stage IV gastric cancer (GC).
Qiang Xue(Tianjin Medical University Cancer Institute and Hospital), Han Liang(Sun Yat-sen University), Wenbai Huang(Tianjin Medical University Cancer Institute and Hospital), Hongjie Zhan, Xuejun Wang(Shandong Center for Disease Control and Prevention), Bin Li(State Key Laboratory of Respiratory Disease), Yong Liu(Chengdu Medical College), Hongmin Liu(Tianjin Medical University Cancer Institute and Hospital), Xuewei Ding(Tianjin Medical University Cancer Institute and Hospital), Mingzhi Cai(Tianjin Medical University Cancer Institute and Hospital), Ning Liu, Xiaona Wang(Zhengzhou University), Liangliang Wu(Beijing Institute of Aeronautical Materials), Bin Ke(Tianjin Medical University Cancer Institute and Hospital), Baogui Wang(Tianjin Medical University Cancer Institute and Hospital), Jingyu Deng(Tianjin Medical University Cancer Institute and Hospital), Yan Sun(Tianjin Medical University General Hospital)
Cited by 6
Related Papers
Targeting PI3K/Akt signal transduction for cancer therapy
|Signal Transduction and Targeted Therapy|2021|1.7k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Advances in targeted therapy for esophageal cancer
|Signal Transduction and Targeted Therapy|2020|546
Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment
|MedComm|2021|369
AutoCompress: An Automatic DNN Structured Pruning Framework for Ultra-High Compression Rates
|Proceedings of the AAAI Conference on Artificial Intelligence|2020|195